Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CRYAB | P02511 | 1/20 | 0.60 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 3/20 | 0.54 |
| ▸ | PTGES | O14684 | 3/20 | 0.49 |
| ▸ | ACLY | P53396 | 2/20 | 0.48 |
| ▸ | ACACA | Q13085 | 2/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30651915 | 1.00 | MAPK1 (0.61) | MAPK1USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL26642848 | 1.00 | MAPK1 (0.61) | MAPK1USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL28676116 | 1.00 | MAPK1 (0.61) | MAPK1USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL31097469 | 0.91 | MAPK1 (0.75) | MAPK1USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL1196805 | 0.87 | MAPK1 (0.50) | MAPK1USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL1196806 | 0.87 | MAPK1 (0.50) | MAPK1USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL13384621 | 0.86 | HMGCR (0.58) | MAPK1USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL19728965 | 0.84 | MAPK1 (0.48) | MAPK1USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL29934958 | 0.83 | MAPK1 (0.47) | MAPK1USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL3303674 | 0.82 | TOP2A (0.63) | MAPK1USP2ALDH1A1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | MAPK1 4367/4885USP2 2046/4885ALDH1A1 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.